Aurobindo Pharma in discussion with Actavis to buy API units in Western Europe: Report

13 Jan 2014 Evaluate

Aurobindo Pharma is reportedly in discussion with global pharma giant Actavis to buy their Active Pharmaceutical Ingredients (API) units in Western Europe. The move is in line with the Aurobindo’s strategy to vertically integrate their injectables business by buying ingredient making units.

Actavis is likely to sell loss making units in Italy, Spain, France, Germany and the Netherlands. The API units have revenue of close to $500 million.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

 

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×